ArticleSurgical endoscopy2026
Clinical utility of single-balloon enteroscopy for malignant small bowel tumors.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate pre-treatment characterization of small bowel tumors (SBTs) is essential because therapeutic strategies differ markedly by pathology. Although single-balloon enteroscopy (SBE) enables direct visualization, localization, and biopsy, its clinical utility for treatment planning in malignant SBTs remains insufficiently characterized.
methodsThis retrospective single-center study included patients who underwent SBE for suspected SBTs between September 2005 and July 2024, excluding hereditary polyposis syndromes. The analysis was restricted to malignant lesions; therefore, diagnostic-performance indices were not estimated. Outcomes were establishment of an SBE-derived pre-treatment diagnosis, concordance among these lesions, lesion reach rate, biopsy yield, tattooing rate, and avoidance of surgery required for diagnosis.
resultsAmong 1407 SBE examinations in 1089 patients, 86 malignant lesions in 85 patients were analyzed. The most common indication was obscure gastrointestinal bleeding (36.0%). Malignant lymphoma was most frequent (40.7%), followed by adenocarcinoma (22.1%), gastrointestinal stromal tumor (18.6%), and metastatic carcinoma (12.8%). The target lesion was reached in 84.9% (73/86). An SBE-derived pre-treatment diagnosis was established in 75.6% (65/86), with 95.4% (62/65) concordance with the final diagnosis. Biopsy yielded pathological confirmation in 92.9% (52/56); the intention-to-diagnose yield was 60.5% (52/86). Tattooing was performed in 65.6% (40/61) of treated lesions overall and 83.3% (40/48) of reached treated lesions. Diagnostic surgery was avoided in 75.6% (65/86) of lesions overall and 82.9% (29/35) of malignant lymphoma lesions.
conclusionsIn this malignant SBT cohort, SBE provided clinically useful information for lesion localization, histological confirmation, and treatment planning. Diagnostic surgery was avoided in 75.6% of lesions; however, this descriptive workflow finding should not be interpreted as a demonstrated causal effect of SBE.
Indexed as
Identifiers
42576077What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.